A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Status:
Recruiting
Trial end date:
2025-09-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare belzutifan to everolimus with respect to
progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1
(RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare
everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is
superior to everolimus with respect to PFS and OS.